Literature DB >> 20483750

Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2.

Johann Röhrl1, De Yang, Joost J Oppenheim, Thomas Hehlgans.   

Abstract

Beta-defensins play a dual role during immune response. Their direct antimicrobial properties contribute to the local innate immune response by combating microbial invasions. Furthermore, previous studies revealed the capacity of certain beta-defensin family members to chemoattract immature dendritic cells and CD45RO+ CD4+ T cells through chemokine receptor CCR6. However, because beta-defensins also chemoattract macrophages and monocytes, which do not express CCR6, efforts have been made to identify other receptors for these polypeptides. In this study, we demonstrate the capacity of human beta-defensin (hBD)2 and 3 and their mouse orthologs, beta-defensin 4 and 14, to interact with CCR2, a chemokine receptor expressed on monocytes, macrophages, and neutrophils. These beta-defensins, fused to the Fc region of human IgG1, showed binding to CCR2-transfected HEK293 cells, as revealed by flow cytometry. The beta-defensin fusion proteins also induced CCR2-specific chemotaxis of transfected HEK293 cells, human peripheral blood monocytes, and mouse peritoneal exudate cells in a dose-dependent manner. Preincubation of human monocytes with CCL2/MCP-1, the chemokine ligand for CCR2, abolished migration induced by beta-defensins. Conversely, preincubation with hBD2:Ig or hBD3:Ig inhibited MCP-1 induced migration. Peritoneal exudate cells from CCR2-deficient mice failed to migrate toward these fusion proteins. In conclusion, the beta-defensins used in this study contribute to the innate and adaptive immune response in their role as chemoattractants. Our data indicate that hBD2 and hBD3, together with their mouse orthologs (beta-defensin 4 and 14), are chemotactic for a broad spectrum of leukocytes in a CCR6- and CCR2-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483750      PMCID: PMC6309988          DOI: 10.4049/jimmunol.0903984

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  Defensins of vertebrate animals.

Authors:  Robert I Lehrer; Tomas Ganz
Journal:  Curr Opin Immunol       Date:  2002-02       Impact factor: 7.486

2.  Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia.

Authors:  J Harder; U Meyer-Hoffert; L M Teran; L Schwichtenberg; J Bartels; S Maune; J M Schröder
Journal:  Am J Respir Cell Mol Biol       Date:  2000-06       Impact factor: 6.914

3.  Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis.

Authors:  K J Katschke; J B Rottman; J H Ruth; S Qin; L Wu; G LaRosa; P Ponath; C C Park; R M Pope; A E Koch
Journal:  Arthritis Rheum       Date:  2001-05

4.  Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.

Authors:  A Biragyn; M Surenhu; D Yang; P A Ruffini; B A Haines; E Klyushnenkova; J J Oppenheim; L W Kwak
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

5.  The structure of human beta-defensin-2 shows evidence of higher order oligomerization.

Authors:  D M Hoover; K R Rajashankar; R Blumenthal; A Puri; J J Oppenheim; O Chertov; J Lubkowski
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

6.  Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein.

Authors:  T Birchler; R Seibl; K Büchner; S Loeliger; R Seger; J P Hossle; A Aguzzi; R P Lauener
Journal:  Eur J Immunol       Date:  2001-11       Impact factor: 5.532

7.  Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse.

Authors:  Donna M Dambach; Linda M Watson; Kevin R Gray; Stephen K Durham; Debra L Laskin
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

8.  CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium.

Authors:  M N Becker; G Diamond; M W Verghese; S H Randell
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

9.  Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6.

Authors:  D Yang; O Chertov; S N Bykovskaia; Q Chen; M J Buffo; J Shogan; M Anderson; J M Schröder; J M Wang; O M Howard; J J Oppenheim
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

10.  Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction.

Authors:  J R García; F Jaumann; S Schulz; A Krause; J Rodríguez-Jiménez; U Forssmann; K Adermann; E Klüver; C Vogelmeier; D Becker; R Hedrich; W G Forssmann; R Bals
Journal:  Cell Tissue Res       Date:  2001-11       Impact factor: 5.249

View more
  112 in total

1.  Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules.

Authors:  Sascha Jung; Justyna Mysliwy; Björn Spudy; Inken Lorenzen; Karina Reiss; Christoph Gelhaus; Rainer Podschun; Matthias Leippe; Joachim Grötzinger
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

Review 2.  Immune modulation by multifaceted cationic host defense (antimicrobial) peptides.

Authors:  Ashley L Hilchie; Kelli Wuerth; Robert E W Hancock
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

3.  Phenol-soluble modulin α induces G2/M phase transition delay in eukaryotic HeLa cells.

Authors:  Martine Deplanche; Rachid Aref El-Aouar Filho; Ludmila Alekseeva; Emilie Ladier; Julien Jardin; Gwénaële Henry; Vasco Azevedo; Anderson Miyoshi; Laetitia Beraud; Frederic Laurent; Gerard Lina; François Vandenesch; Jean-Paul Steghens; Yves Le Loir; Michael Otto; Friedrich Götz; Nadia Berkova
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

4.  Human β-defensin-3 structure motifs that are important in CXCR4 antagonism.

Authors:  Zhimin Feng; George R Dubyak; Xun Jia; Jacek T Lubkowski; Aaron Weinberg
Journal:  FEBS J       Date:  2013-06-07       Impact factor: 5.542

Review 5.  Amplifying renal immunity: the role of antimicrobial peptides in pyelonephritis.

Authors:  Brian Becknell; Andrew Schwaderer; David S Hains; John David Spencer
Journal:  Nat Rev Nephrol       Date:  2015-07-07       Impact factor: 28.314

6.  The antimicrobial peptide human beta-defensin 2 promotes itch through Toll-like receptor 4 signaling in mice.

Authors:  Jing Feng; Jialie Luo; Madison R Mack; Pu Yang; Feng Zhang; Guan Wang; Xuan Gong; Tao Cai; Zhinan Mei; Brian S Kim; Shijin Yin; Hongzhen Hu
Journal:  J Allergy Clin Immunol       Date:  2017-04-23       Impact factor: 10.793

7.  Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.

Authors:  Laura A Novotny; John D Clements; Lauren O Bakaletz
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  Phosphoproteomic characterization of the signaling network resulting from activation of the chemokine receptor CCR2.

Authors:  Cheng Huang; Simon R Foster; Anup D Shah; Oded Kleifeld; Meritxell Canals; Ralf B Schittenhelm; Martin J Stone
Journal:  J Biol Chem       Date:  2020-04-02       Impact factor: 5.157

9.  Antimicrobial peptides in gastrointestinal inflammation.

Authors:  Simon Jäger; Eduard F Stange; Jan Wehkamp
Journal:  Int J Inflam       Date:  2010-11-25

Review 10.  Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases.

Authors:  Hariharan Subramanian; Kshitij Gupta; Hydar Ali
Journal:  J Allergy Clin Immunol       Date:  2016-07-20       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.